Search Results - "Petrie, John"

Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms by Petrie, John R., Guzik, Tomasz J., Touyz, Rhian M.

“…Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have…”
Get full text

Metformin beyond type 2 diabetes: Emerging and potential new indications by Petrie, John R.

“…Metformin is best known as a foundational therapy for type 2 diabetes but is also used in other contexts in clinical medicine with a number of emerging and…”
Get full text

Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review by Boyle, James G, Livingstone, Rachel, Petrie, John R

“…Type 2 diabetes (T2D) carries risks of both cardiovascular (CV) (myocardial infarction, stroke, and peripheral vascular disease) and microvascular…”
Get more information

Excess Cardiovascular Risk in Type 1 Diabetes Mellitus: Role for a Dysfunctional Immune Response? by Petrie, John R, Sattar, Naveed

Get full text

Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group by Fleming, G Alexander, Petrie, John R, Bergenstal, Richard M, Holl, Reinhard W, Peters, Anne L, Heinemann, Lutz

“…Digital health technology, especially digital and health applications ("apps"), have been developing rapidly to help people manage their diabetes. Numerous…”
Get full text

A new perspective on metformin therapy in type 1 diabetes by Livingstone, Rachel, Boyle, James G., Petrie, John R.

“…Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in…”
Get full text

SGLT2 inhibitors and renal complications in type 1 diabetes by Petrie, John R

Get full text

Metformin, lipids and atherosclerosis prevention by Jenkins, Alicia J, Welsh, Paul, Petrie, John R

“…We provide an overview of recent publications that extend clinically relevant knowledge relating to metformin's effects on lipids and atherosclerotic vascular…”
Get full text

Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study by Livingstone, Shona J, Looker, Helen C, Hothersall, Eleanor J, Wild, Sarah H, Lindsay, Robert S, Chalmers, John, Cleland, Stephen, Leese, Graham P, McKnight, John, Morris, Andrew D, Pearson, Donald W M, Peden, Norman R, Petrie, John R, Philip, Sam, Sattar, Naveed, Sullivan, Frank, Colhoun, Helen M

“…Randomized controlled trials have shown the importance of tight glucose control in type 1 diabetes (T1DM), but few recent studies have evaluated the risk of…”
Get full text

Identification of novel biomarkers to monitor β-cell function and enable early detection of type 2 diabetes risk by Belongie, Kirstine J, Ferrannini, Ele, Johnson, Kjell, Andrade-Gordon, Patricia, Hansen, Michael K, Petrie, John R

“…A decline in β-cell function is a prerequisite for the development of type 2 diabetes, yet the level of β-cell function in individuals at risk of the condition…”
Get full text

Metformin and cardiorenal outcomes in diabetes: A reappraisal by Petrie, John R., Rossing, Peter R., Campbell, Ian W.

“…The guidance issued to the pharmaceutical industry by the US Food and Drug Administration in 2008 has led to the publication of a series of randomized,…”
Get full text

Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations: A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group by Petrie, John R, Peters, Anne L, Bergenstal, Richard M, Holl, Reinhard W, Fleming, G Alexander, Heinemann, Lutz

“…The first systems for continuous glucose monitoring (CGM) became available over 15 years ago. Many then believed CGM would revolutionize the use of intensive…”
Get full text

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care by Marx, Nikolaus, Davies, Melanie J, Grant, Peter J, Mathieu, Chantal, Petrie, John R, Cosentino, Francesco, Buse, John B

“…Cardiovascular outcome trials in patients with type 2 diabetes at high cardiovascular risk have led to remarkable advances in our understanding of the…”
Get full text

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF) by Lee, Matthew M.Y., Brooksbank, Katriona J.M., Wetherall, Kirsty, Mangion, Kenneth, Roditi, Giles, Campbell, Ross T., Berry, Colin, Chong, Victor, Coyle, Liz, Docherty, Kieran F., Dreisbach, John G., Labinjoh, Catherine, Lang, Ninian N., Lennie, Vera, McConnachie, Alex, Murphy, Clare L., Petrie, Colin J., Petrie, John R., Speirits, Iain A., Sourbron, Steven, Welsh, Paul, Woodward, Rosemary, Radjenovic, Aleksandra, Mark, Patrick B., McMurray, John J.V., Jhund, Pardeep S., Petrie, Mark C., Sattar, Naveed

“…Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with heart failure and reduced…”
Get full text

The cardiovascular safety of incretin-based therapies: a review of the evidence by Petrie, John R

“…Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a…”
Get full text

Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010 by Livingstone, Shona J, Levin, Daniel, Looker, Helen C, Lindsay, Robert S, Wild, Sarah H, Joss, Nicola, Leese, Graham, Leslie, Peter, McCrimmon, Rory J, Metcalfe, Wendy, McKnight, John A, Morris, Andrew D, Pearson, Donald W. M, Petrie, John R, Philip, Sam, Sattar, Naveed A, Traynor, Jamie P, Colhoun, Helen M

“…IMPORTANCE: Type 1 diabetes has historically been associated with a significant reduction in life expectancy. Major advances in treatment of type 1 diabetes…”
Get full text

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes by Nauck, Michael A, Petrie, John R, Sesti, Giorgio, Mannucci, Edoardo, Courrèges, Jean-Pierre, Lindegaard, Marie L, Jensen, Christine B, Atkin, Stephen L

“…To investigate the dose-response relationship of semaglutide versus placebo and open-label liraglutide in terms of glycemic control in patients with type 2…”
Get full text

Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association by Sherr, Jennifer L, Heinemann, Lutz, Fleming, G Alexander, Bergenstal, Richard M, Bruttomesso, Daniela, Hanaire, Hélène, Holl, Reinhard W, Petrie, John R, Peters, Anne L, Evans, Mark

“…A technological solution for the management of diabetes in people who require intensive insulin therapy has been sought for decades. The last 10 years have…”
Get full text

Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association by Sherr, Jennifer L., Heinemann, Lutz, Fleming, G. Alexander, Bergenstal, Richard M., Bruttomesso, Daniela, Hanaire, Hélène, Holl, Reinhard W., Petrie, John R., Peters, Anne L., Evans, Mark

“…A technological solution for the management of diabetes in people who require intensive insulin therapy has been sought for decades. The last 10 years have…”
Get full text

Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group by Fleming, G. Alexander, Petrie, John R., Bergenstal, Richard M., Holl, Reinhard W., Peters, Anne L., Heinemann, Lutz

“…Digital health technology, especially digital and health applications (‘apps’), have been developing rapidly to help people manage their diabetes. Numerous…”
Get full text